Kymera Therapeutics, Inc.
KYMR
$57.84
-$3.16-5.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -82.18M | -76.61M | -65.58M | -70.75M | -62.49M |
| Total Depreciation and Amortization | 2.15M | 2.08M | 2.05M | 1.99M | 1.99M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.47M | 13.30M | 11.71M | 10.53M | 11.28M |
| Change in Net Operating Assets | 35.45M | 1.35M | -27.33M | -3.55M | -971.00K |
| Cash from Operations | -27.11M | -59.88M | -79.15M | -61.78M | -50.19M |
| Capital Expenditure | -181.00K | -695.00K | -467.00K | -936.00K | 189.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -235.12M | 60.72M | 49.08M | 69.50M | -157.87M |
| Cash from Investing | -235.30M | 60.02M | 48.62M | 68.57M | -157.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -419.00K | -382.00K | -277.00K | -293.00K | -641.00K |
| Issuance of Common Stock | 39.93M | 246.11M | 535.00K | 31.42M | 251.56M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -28.36M | -- |
| Cash from Financing | 39.51M | 245.73M | 258.00K | 2.77M | 250.92M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -222.90M | 245.86M | -30.28M | 9.55M | 43.05M |